Vanda Pharmaceuticals Inc
$ 7.16
-1.51%
16 Apr - close price
- Market Cap 423,214,000 USD
- Current Price $ 7.16
- High / Low $ 7.28 / 7.02
- Stock P/E N/A
- Book Value 5.54
- EPS -3.74
- Next Earning Report 2026-05-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.16 %
- ROE -0.51 %
- 52 Week High 9.94
- 52 Week Low 3.81
About
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company is headquartered in Washington, the District of Columbia.
Analyst Target Price
$15.50
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-11 | 2025-11-05 | 2025-07-31 | 2025-05-07 | 2025-02-13 | 2024-11-06 | 2024-07-31 | 2024-05-08 | 2024-02-07 | 2023-11-08 | 2023-07-27 | 2023-05-03 |
| Reported EPS | -1.81 | -0.38 | -0.46 | -0.5 | -0.08 | -0.09 | -0.08 | -0.0718 | -0.04 | 0.0024 | 0.03 | 0.06 |
| Estimated EPS | -0.98 | -0.45 | -0.36 | -0.6 | -0.11 | -0.16 | -0.21 | 0.05 | -0.09 | -0.04 | -0.13 | 0.06 |
| Surprise | -0.83 | 0.07 | -0.1 | 0.1 | 0.03 | 0.07 | 0.13 | -0.1218 | 0.05 | 0.0424 | 0.16 | 0 |
| Surprise Percentage | -84.6939% | 15.5556% | -27.7778% | 16.6667% | 27.2727% | 43.75% | 61.9048% | -243.6% | 55.5556% | 106% | 123.0769% | 0% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.53 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: VNDA
2026-04-14 18:39:50
This article provides an overview of Polymeropoulos Christos Vasilios Mihael's net worth and insider trading activities, highlighting his ownership in Vanda Pharmaceuticals Inc (VNDA) where he serves as Senior VP & Medical Director. It details that he has made no insider transactions in VNDA recently, while other insiders have conducted net sales of shares. The article also lists key executives at Vanda Pharmaceuticals Inc and summarizes recent insider trading in the company.
2026-04-14 11:10:14
Vanda Pharmaceuticals (NASDAQ:VNDA) experienced a significant increase in short interest, rising 65.9% to 5,310,265 shares by March 31st. This represents approximately 10.0% of the company's shares being shorted. The company missed Q4 earnings expectations with a negative EPS of ($2.39) and negative net margin of 102.02%, while analysts forecast approximately -1.12 EPS for the current year.
2026-04-13 21:39:01
Vanda Pharmaceuticals Inc. Senior VP and Medical Director, Christos Vasilios Mihael Polymeropoulos, has filed an initial ownership report detailing his equity positions. The report indicates he holds a stock option for 61,200 shares at $7.05, expiring in 2033, along with several common stock and restricted stock unit (RSU) awards. These RSUs have time-based vesting schedules from March 2027 to March 2029, contingent on continued employment.
2026-04-13 21:37:01
Vanda Pharmaceuticals' VP and Chief People Officer, Howell Scott Laverne, has filed an initial ownership report (Form 3) detailing his holdings in the company. The report reveals a combination of stock options, restricted stock units, and direct and indirect common shares. His equity ownership includes significant stock options expiring in 2033, 2032, 2031, and 2030, along with various RSU awards that vest contingent on continuous employment, and common stock held directly and indirectly through a family foundation.
2026-04-10 11:10:14
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has received a consensus "Moderate Buy" rating from brokerages, with an average 12-month price target of $14.90. The biopharmaceutical company recently reported a quarterly EPS loss of ($2.39) and missed revenue estimates. Insider selling and institutional ownership changes have also been noted.
2026-04-09 15:39:42
Vanda Pharmaceuticals has criticized an FDA proposal to eliminate the 180-day review timeline for new drug applications, arguing it violates current law and could extend review periods. The company, which has seen strong stock performance and is predicted to become profitable, urged the FDA to withdraw the proposal and Congress to reject it. This comes amidst other news for Vanda, including a new clinical trial and analyst ratings.
